Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2025.21.909.508 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Biomarkers of IgA Nephropathy.
Semin Nephrol
March 2025
Department of Medicine, Division of Nephrology, Stanford University, Stanford, CA, USA. Electronic address:
IgA nephropathy (IgAN) is the most prevalent primary glomerular disease and has been recognized to carry a poor prognosis. It is therefore critical to identify the patients that will progress to ESKD and start treatments early. The current gold standard for diagnosis remains kidney biopsy.
View Article and Find Full Text PDFComparison of hook plates vs. locking plates for Neer type IIB fractures of lateral end clavicle: A systematic review.
Chin J Traumatol
February 2025
Department of Trauma and Orthopaedics, Scunthorpe General Hospital, Scunthorpe, DN15 7BH, United Kingdom.
Purpose: Surgical management of the lateral end of clavicle fractures has been a challenge for orthopedic surgeons considering the high rate of non-union. There has been no right and wrong answer to these types of fractures and many methods discussed in the literature, but the 2 most used bony procedures are hook plate and locking plate with or without the use of supplementary soft tissue procedures. The available evidence, in this case, is scarce with questionable reliability.
View Article and Find Full Text PDFAntidiabetic Drugs Consumption in France Over a Decade: An Observational Study.
Clin Ther
March 2025
Nutrition Department, Hopital Européen Georges Pompidou, AP-HP, Paris Cité University, Paris, France; CIC1418, Hopital Européen Georges Pompidou, AP-HP, Paris Cité University, Paris, France.
Aims: The prevalence of type 2 diabetes has increased in France over the past decade, with changes in available pharmacologic treatments. This study aimed to assess trends in the sales of antidiabetic drugs in France over the last decade.
Methods: This retrospective cohort study used data from French national health insurance databases.
Motor cortex repetitive transcranial magnetic stimulation in fibromyalgia: a multicentre randomised controlled trial.
Br J Anaesth
March 2025
LIM 62 - Pain Center, Department of Neurology, São Paulo, Brazil; Center for Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, University of Aalborg, Gistrup, Denmark. Electronic address:
Background: Despite affecting 2-4% of the population worldwide, fibromyalgia often remains refractory to treatment. Here we report the first international randomised double-blind, sham-controlled trial developed to assess the efficacy of repetitive transcranial magnetic stimulation (rTMS) as an add-on therapy for fibromyalgia.
Methods: Women aged ≥18 yr with fibromyalgia refractory to best available treatment were enrolled in Brazil, France, and Japan, and randomised to 10 Hz motor cortex (M1) rTMS, 3000 pulses day, or sham stimulation.
Application of silica monoliths for improved storage stability of metabolites in human plasma.
J Biosci Bioeng
March 2025
Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Osaka University Shimadzu Analytical Innovation Research Laboratory, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address:
In metabolomic studies, sample collection and analysis are typically performed at separate locations, necessitating the transport and storage of samples. However, sample transport and storage conditions are often constrained by the available facilities. Specifically, metabolite levels in biological and food samples can fluctuate due to the activity of endogenous enzymes, depending on the transport and storage conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!